All of those were certainly possibilities. But the multiple articles talking about SRPT's interest in a broad-acting DMD drug and fact that utrophin was specifically cited was part of why I thought this partnership had a good chance of coming to fruition.
Yes, you have a good memory. ARRY did this on a few occasions. I think the deal with AMGN on the glucokinase activator for diabetes caused a 30 or 40% pop in shares. This is why, for me, it's always important to pay close attention to CCs for clues from management, if not outright guidance, on events to come. You can also look for shifts in management tone, in general or on specific drugs for clues as to how things may be going.